Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Oramed Pharmaceuticals Inc. Stories

2014-04-10 08:30:20

JERUSALEM, April 10, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Hong Kong has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins." About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the...

2014-03-27 08:34:50

JERUSALEM, March 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM). "We are pleased to be initiating this U.S. clinical trial with ORMD-0801 in...

2014-03-11 08:30:59

JERUSALEM, March 11, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office, has issued the Company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's...

2014-03-06 08:31:53

Presentations Scheduled at Barclays Global Healthcare Conference, BioPharma Asia Convention and ROTH Growth Stock Conference in March JERUSALEM, March 6, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com [ \\lonpivdocs\Aviva - Oramed\EFN Synced Tool\.CORPORATE\Public Relations\Press Releases\Press Releases\2014\NEW RELEASES - checking\www.oramed.com ]), a clinical-stage pharmaceutical company focused on the development of oral drug...

2014-03-03 08:32:04

Podium Presentation Highlighting Safety and Efficacy Data to be Presented by the Company's CSO, Dr. Miriam Kidron JERUSALEM, March 3, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule...

2014-02-10 12:25:17

JERUSALEM, Feb. 10, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted a protocol to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. The protocol was submitted under Oramed's existing IND for ORMD-0801 to include both...

2014-02-04 08:35:52

NEW YORK, Feb. 4, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (NasdaqCM: ORMP). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. The investigation concerns whether Oramed and certain of its officers and/or directors...

2014-02-03 12:29:42

NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oramed Pharmaceuticals, Inc. ("Oramed" or the "Company") (NasdaqGS: ORMP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The investigation concerns whether Oramed and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On Monday February 3, 2014,...

2014-01-30 04:22:02

Company to Move Forward with FDA Phase 2b Multi-Center Trial JERUSALEM, Jan. 30, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration (FDA) IND (Investigational New Drug) protocol. The Phase 2a study met all primary and...

2014-01-27 08:28:47

JERUSALEM, January 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. [http://www.oramed.com ] (NASDAQCM: ORMP) ( http://www.oramed.com), a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 [http://www.oramed.com/index.php?page=14 ] oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014. Oramed CEO Nadav Kidron will present the findings at an investor...